ReviewNature reviews. Gastroenterology & hepatology2016
Breakthroughs in the treatment and prevention of Clostridium difficile infection.
Review in Nature reviews. Gastroenterology & hepatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 2 syntheses or guidelines pooled it, 146 citations in OpenAlex.
- Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile).The Cochrane database of systematic reviews · 2023Pooled it
- Global prevalence of prolonged gastrointestinal symptoms in COVID-19 survivors and potential pathogenesis: A systematic review and meta-analysis.F1000Research · 2021Pooled it
- Synthetic PS-III Glycoconjugate Vaccines Based on Solid-Phase Assembled Well-Defined Oligosaccharides Confers Protection againstACS central science · 2026Article
- Carbadox, a veterinary growth promoter exhibits anticlostridial activity through induction of oxidative stress in Clostridioides difficile.Gut pathogens · 2026Article
- Bacteriocin-transport-inspired oral peptide-probiotic delivery ameliorates IBD complications via autophagy and gut homeostasis.Science advances · 2026Article
- Glycopeptides: Insights Towards Resistance, Clinical Pharmacokinetics and Pharmacodynamics.Indian journal of microbiology · 2025Article
- The link between gut microbiota and multiple sclerosis from the perspective of barrier function.Frontiers in immunology · 2025Review
- Mechanisms ofFrontiers in cellular and infection microbiology · 2025Review
- A Retrospective Assessment of Guideline Adherence and Treatment Outcomes FromOpen forum infectious diseases · 2024Article
- Fecal microbiota transplantation: current challenges and future landscapes.Clinical microbiology reviews · 2024Review
- Porcine Monocyte DNA Traps Formed during Infection with PathogenicPathogens (Basel, Switzerland) · 2024Article
- Defined microbial communities and their soluble products protect mice from Clostridioides difficile infection.Communications biology · 2024Article
- Article
- Biofilm Formation ofMicroorganisms · 2023Review
- Synergistic mediating effect of edible fungal polysaccharides (Food science & nutrition · 2023Article
- Comparison of DNA extraction methods for 16S rRNA gene sequencing in the analysis of the human gut microbiome.Scientific reports · 2023Article
- CDBN-YGXZ, a Novel Small-Molecule Drug, Shows Efficacy against Clostridioides difficile Infection and Recurrence in Mouse and Hamster Infection Models.Antimicrobial agents and chemotherapy · 2023Article
- Probiotics: insights and new opportunities forCritical reviews in microbiology · 2023Review
- Detection of EnterotoxigenicLife (Basel, Switzerland) · 2023Article
- Diversity, Dynamics and Therapeutic Application ofViruses · 2022Review
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This Review summarizes the latest advances in the treatment and prevention of Clostridium difficile infection (CDI), which is now the most common health-care-associated infection in the USA. As traditional, standard CDI antibiotic therapies (metronidazole and vancomycin) are limited by their broad spectrum and further perturbation of the intestinal microbiota, which result in unacceptably high recurrence rates, novel therapeutic strategies for CDI are needed. Emerging CDI therapies are focused on limiting further perturbation of the intestinal microbiota and/or restoring the microbiota to its pre-morbid state, reducing colonization of the intestinal tract by toxigenic strains of C. difficile and bolstering the host immune response against C. difficile toxins. Fidaxomicin is associated with reduced CDI recurrences, and other emerging narrow-spectrum CDI antibiotic therapies might eventually demonstrate a similar benefit. Prevention of intestinal colonization of toxigenic strains of C. difficile can be achieved through restoration of the intestinal microbiota with faecal microbiota transplantation, as well as by colonizing the gut with nontoxigenic C. difficile strains. Finally, emerging immunological therapies, including monoclonal antibodies and vaccines against C. difficile toxins, might protect against CDI and subsequent CDI recurrences. The available clinical data for these emerging therapies, and their relative advantages and disadvantages, are described.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.